The National Institute for Health and Clinical Excellence (NICE) has today (23 February) published final guidance to the NHS not recommending the use of bevacizumab (Avastin, Roche Products), when used in combination with a taxane (a type of chemotherapy drug), as a first-line treatment for people with metastatic breast cancer...
More...
Linear Mode
